{"slug":"glioma","tag":"glioma","variants":["glioma"],"description":"No description yet","count":9,"kinds":{"person":7,"biomarker":2},"related":[{"slug":"biomarker","tag":"biomarker","shared":2},{"slug":"paediatric","tag":"paediatric","shared":2},{"slug":"biomarkers","tag":"biomarkers","shared":1},{"slug":"cancer-neuroscience","tag":"cancer-neuroscience","shared":1},{"slug":"car-t","tag":"car-t","shared":1},{"slug":"chemotherapy","tag":"chemotherapy","shared":1},{"slug":"eortc","tag":"eortc","shared":1},{"slug":"idh","tag":"idh","shared":1},{"slug":"immunotherapy","tag":"immunotherapy","shared":1},{"slug":"mgmt","tag":"mgmt","shared":1},{"slug":"neoadjuvant","tag":"neoadjuvant","shared":1},{"slug":"neuro-oncology","tag":"neuro-oncology","shared":1}],"records":[{"id":"ingo-mellinghoff","kind":"person","name":"Ingo K. Mellinghoff","route":"/people/ingo-mellinghoff/","tldr":"Led INDIGO, the trial that made vorasidenib the first targeted therapy for low-grade IDH-mutant glioma."},{"id":"patrick-wen","kind":"person","name":"Patrick Y. Wen","route":"/people/patrick-wen/","tldr":"Neuro-oncologist who created the RANO response criteria used in every brain tumour trial and leads glioblastoma drug development."},{"id":"martin-van-den-bent","kind":"person","name":"Martin J. van den Bent","route":"/people/martin-van-den-bent/","tldr":"Led the EORTC glioma trials that established chemotherapy for anaplastic gliomas and the value of 1p/19q and IDH status."},{"id":"monika-hegi","kind":"person","name":"Monika E. Hegi","route":"/people/monika-hegi/","tldr":"Showed that MGMT promoter methylation predicts benefit from temozolomide, the biomarker every glioblastoma patient is now tested for."},{"id":"mitchel-berger","kind":"person","name":"Mitchel S. Berger","route":"/people/mitchel-berger/","tldr":"Neurosurgeon who proved that removing more of a glioma extends survival and pioneered awake mapping to do it safely."},{"id":"timothy-cloughesy","kind":"person","name":"Timothy F. Cloughesy","route":"/people/timothy-cloughesy/","tldr":"Neuro-oncologist whose neoadjuvant PD-1 trial showed immunotherapy before surgery can activate immune responses in glioblastoma."},{"id":"michelle-monje","kind":"person","name":"Michelle Monje","route":"/people/michelle-monje/","tldr":"Founded cancer neuroscience and led the GD2 CAR-T trial that produced the first regressions of diffuse midline glioma."},{"id":"1p19q-codeletion-readout","kind":"biomarker","name":"1p/19q codeletion","route":"/biomarkers/1p19q-codeletion-readout/","tldr":"Loss of one copy each of chromosome arms 1p and 19q, together with an IDH mutation, defines oligodendroglioma in the WHO 2021 classification. It predicts a slower course and a good response to chemotherapy, and separates oligodendroglioma from astrocytoma."},{"id":"h3-k27m","kind":"biomarker","name":"H3 K27M mutation","route":"/biomarkers/h3-k27m/","tldr":"H3 K27M is a single change in a histone that defines diffuse midline glioma, including the brain-stem tumour DIPG. In 2025 dordaviprone became the first drug approved for tumours carrying it."}]}